# CNR1

## Overview
The CNR1 gene encodes the cannabinoid receptor 1 (CB1), a G protein-coupled receptor (GPCR) that plays a pivotal role in the endocannabinoid system. This receptor is predominantly expressed in the central nervous system, where it modulates neurotransmitter release and synaptic transmission, influencing various physiological processes such as memory, mood, and motor control (Tao2020Cannabinoid). Structurally, CB1 is characterized by seven transmembrane alpha-helices, a hallmark of GPCRs, and features a ligand-binding pocket that exhibits significant plasticity, allowing it to interact with a diverse array of ligands (Krishna2019Structure; Hua2017Crystal). Beyond the central nervous system, CB1 is also involved in peripheral functions, including energy balance and metabolism, by influencing adipocyte differentiation and lipid metabolism (Pagano2007The; Quarta2011Energy). The receptor's interactions with various proteins, such as CRIP1a and GASP1, further modulate its signaling pathways and functional outcomes (FletcherJones2020Protein; Blume2016Cannabinoid). Variations in the CNR1 gene have been linked to several neurological and psychiatric disorders, highlighting its clinical significance in conditions like depression, anxiety, and metabolic disorders (de2011Variants; Smith2017Rare).

## Structure
The CNR1 gene encodes the cannabinoid receptor 1 (CB1), a G protein-coupled receptor (GPCR) predominantly located in the central nervous system. The primary structure of CB1 consists of a sequence of amino acids forming seven transmembrane alpha-helices, characteristic of GPCRs (Krishna2019Structure). The secondary structure involves these helices, which are integral to the receptor's ability to traverse the cell membrane and facilitate signal transduction.

The tertiary structure of CB1 is defined by the folding of these helices into a three-dimensional conformation, creating a ligand-binding pocket. This pocket is distinct from other class A GPCRs, with significant conformational changes observed when transitioning between agonist and antagonist states (Hua2017Crystal). The receptor's binding pocket is notably plastic, allowing it to accommodate a variety of ligands, which is crucial for its function (Hua2017Crystal).

Post-translational modifications such as glycosylation and palmitoylation influence the receptor's function and localization, although specific details on these modifications are not extensively covered in the provided context. The receptor's structure also includes a 'twin toggle switch' mechanism involving Phe200 and Trp356, which is essential for receptor activation (Hua2017Crystal).

## Function
The CNR1 gene encodes the cannabinoid receptor type 1 (CB1), a G protein-coupled receptor primarily located in the central nervous system (CNS) and expressed in both central and peripheral tissues. CB1 is a critical component of the endocannabinoid system (ECS), which plays a significant role in modulating neurotransmitter release and synaptic transmission. It is predominantly found on presynaptic neurons, where it inhibits the release of various neurotransmitters, including acetylcholine, noradrenaline, serotonin, gamma-aminobutyric acid (GABA), glutamate, and dopamine, thereby influencing processes such as memory, mood, motor control, and reward processing (Tao2020Cannabinoid).

In addition to its role in the CNS, CB1 is involved in regulating energy balance and metabolism. It is expressed in adipose tissue, where it influences adipocyte differentiation, glucose uptake, and lipid metabolism. Activation of CB1 in adipocytes stimulates glucose uptake and lipogenesis, while its blockade can enhance lipolysis and energy expenditure (Pagano2007The; Quarta2011Energy). CB1 also plays a role in appetite regulation, as it is coexpressed with neuropeptides in the hypothalamus that modulate food intake, contributing to the maintenance of body weight (Cota2003The).

## Clinical Significance
Mutations and alterations in the CNR1 gene, which encodes the cannabinoid receptor 1 (CB1), have been associated with a variety of neurological and psychiatric conditions. Rare genetic variants in CNR1 are linked to neurological phenotypes such as migraines, sleep and memory disorders, anxiety, and seizures. These conditions often occur in combination, suggesting a complex interaction between these phenotypes and CNR1 variants (Smith2017Rare).

CNR1 polymorphisms have been implicated in major depression, with certain haplotypes associated with increased risk, particularly in patients with melancholic or psychotic symptoms. These genetic variations may also influence the clinical response to antidepressant treatments like citalopram (Domschke2008Cannabinoid; Mitjans2013Screening).

The CNR1 gene is also associated with Gilles de la Tourette Syndrome, where specific polymorphisms may increase the risk of developing the disorder (Szejko2020Association). Additionally, CNR1 variants have been linked to insulin resistance and type 2 diabetes, suggesting a role in metabolic disorders (de2011Variants).

Alterations in CNR1 expression or function can affect endocannabinoid signaling, potentially contributing to the pathophysiology of conditions like anxiety, schizophrenia, and substance use disorders (Navarro2022Molecular).

## Interactions
The cannabinoid receptor 1 (CB1R), encoded by the CNR1 gene, is involved in various protein interactions that influence its function and signaling pathways. CB1R interacts with Cannabinoid Receptor Interacting Protein 1a (CRIP1a), which competes with β-arrestins for binding sites on the receptor. This competition affects β-arrestin-mediated internalization of CB1R, as CRIP1a overexpression reduces β-arrestin redistribution, while its depletion increases it (Blume2016Cannabinoid). 

CB1R also forms complexes with proteins such as GASP1, CRIP1, and SGIP1, which are crucial for its localization and function (FletcherJones2020Protein). The receptor's C-terminal domain, particularly Helix 8 (H8) and Helix 9 (H9), plays significant roles in protein interactions, trafficking, and signaling. H8 is involved in receptor homodimerization and G protein coupling, while H9 is implicated in membrane retention and ERK1/2 activation (FletcherJones2020Protein).

CB1R interacts with the WAVE1 complex and Rac1, linking it to actin rearrangement in neurons. This interaction affects actin assembly in dendritic spines, highlighting CB1R's role in structural plasticity (Njoo2015The). Additionally, CB1R can heterodimerize with other GPCRs, such as dopamine D2 receptors, altering its signaling pathways (Smith2010Cannabinoid).


## References


[1. (Navarro2022Molecular) Daniela Navarro, Ani Gasparyan, Francisco Navarrete, Abraham B. Torregrosa, Gabriel Rubio, Marta Marín-Mayor, Gabriela B. Acosta, Maria Salud Garcia-Gutiérrez, and Jorge Manzanares. Molecular alterations of the endocannabinoid system in psychiatric disorders. International Journal of Molecular Sciences, 23(9):4764, April 2022. URL: http://dx.doi.org/10.3390/ijms23094764, doi:10.3390/ijms23094764. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23094764)

[2. (Szejko2020Association) Natalia Szejko, Jakub Piotr Fichna, Krzysztof Safranow, Tomasz Dziuba, Cezary Żekanowski, and Piotr Janik. Association of a variant of cnr1 gene encoding cannabinoid receptor 1 with gilles de la tourette syndrome. Frontiers in Genetics, March 2020. URL: http://dx.doi.org/10.3389/fgene.2020.00125, doi:10.3389/fgene.2020.00125. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2020.00125)

[3. (Krishna2019Structure) Kaavya Krishna Kumar, Moran Shalev-Benami, Michael J. Robertson, Hongli Hu, Samuel D. Banister, Scott A. Hollingsworth, Naomi R. Latorraca, Hideaki E. Kato, Daniel Hilger, Shoji Maeda, William I. Weis, David L. Farrens, Ron O. Dror, Sanjay V. Malhotra, Brian K. Kobilka, and Georgios Skiniotis. Structure of a signaling cannabinoid receptor 1-g protein complex. Cell, 176(3):448-458.e12, January 2019. URL: http://dx.doi.org/10.1016/j.cell.2018.11.040, doi:10.1016/j.cell.2018.11.040. This article has 324 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.cell.2018.11.040)

[4. (de2011Variants) Jose M. de Miguel‐Yanes, Alisa K. Manning, Peter Shrader, Jarred B. McAteer, Anuj Goel, Anders Hamsten, Caroline S. Fox, Jose C. Florez, Josée Dupuis, and James B. Meigs. Variants at the endocannabinoid receptor cb1 gene (cnr1) and insulin sensitivity, type 2 diabetes, and coronary heart disease. Obesity, 19(10):2031–2037, October 2011. URL: http://dx.doi.org/10.1038/oby.2011.135, doi:10.1038/oby.2011.135. This article has 16 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/oby.2011.135)

[5. (Tao2020Cannabinoid) Ran Tao, Chao Li, Andrew E. Jaffe, Joo Heon Shin, Amy Deep-Soboslay, Rae’e Yamin, Daniel R. Weinberger, Thomas M. Hyde, and Joel E. Kleinman. Cannabinoid receptor cnr1 expression and dna methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Translational Psychiatry, May 2020. URL: http://dx.doi.org/10.1038/s41398-020-0832-8, doi:10.1038/s41398-020-0832-8. This article has 45 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41398-020-0832-8)

[6. (Smith2010Cannabinoid) Tricia H Smith, Laura J Sim‐Selley, and Dana E Selley. Cannabinoid cb1 receptor‐interacting proteins: novel targets for central nervous system drug discovery? British Journal of Pharmacology, 160(3):454–466, May 2010. URL: http://dx.doi.org/10.1111/j.1476-5381.2010.00777.x, doi:10.1111/j.1476-5381.2010.00777.x. This article has 101 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1111/j.1476-5381.2010.00777.x)

[7. (Njoo2015The) Christian Njoo, Nitin Agarwal, Beat Lutz, and Rohini Kuner. The cannabinoid receptor cb1 interacts with the wave1 complex and plays a role in actin dynamics and structural plasticity in neurons. PLOS Biology, 13(10):e1002286, October 2015. URL: http://dx.doi.org/10.1371/journal.pbio.1002286, doi:10.1371/journal.pbio.1002286. This article has 68 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.pbio.1002286)

[8. (Quarta2011Energy) Carmelo Quarta, Roberta Mazza, Silvana Obici, Renato Pasquali, and Uberto Pagotto. Energy balance regulation by endocannabinoids at central and peripheral levels. Trends in Molecular Medicine, 17(9):518–526, September 2011. URL: http://dx.doi.org/10.1016/j.molmed.2011.05.002, doi:10.1016/j.molmed.2011.05.002. This article has 76 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.molmed.2011.05.002)

[9. (Hua2017Crystal) Tian Hua, Kiran Vemuri, Spyros P. Nikas, Robert B. Laprairie, Yiran Wu, Lu Qu, Mengchen Pu, Anisha Korde, Shan Jiang, Jo-Hao Ho, Gye Won Han, Kang Ding, Xuanxuan Li, Haiguang Liu, Michael A. Hanson, Suwen Zhao, Laura M. Bohn, Alexandros Makriyannis, Raymond C. Stevens, and Zhi-Jie Liu. Crystal structures of agonist-bound human cannabinoid receptor cb1. Nature, 547(7664):468–471, July 2017. URL: http://dx.doi.org/10.1038/nature23272, doi:10.1038/nature23272. This article has 392 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/nature23272)

[10. (Domschke2008Cannabinoid) Katharina Domschke, Udo Dannlowski, Patricia Ohrmann, Bruce Lawford, Jochen Bauer, Harald Kugel, Walter Heindel, Ross Young, Phillip Morris, Volker Arolt, Jürgen Deckert, Thomas Suslow, and Bernhard T. Baune. Cannabinoid receptor 1 (cnr1) gene: impact on antidepressant treatment response and emotion processing in major depression. European Neuropsychopharmacology, 18(10):751–759, October 2008. URL: http://dx.doi.org/10.1016/j.euroneuro.2008.05.003, doi:10.1016/j.euroneuro.2008.05.003. This article has 151 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.euroneuro.2008.05.003)

[11. (Smith2017Rare) Douglas R. Smith, Christine M. Stanley, Theodore Foss, Richard G. Boles, and Kevin McKernan. Rare genetic variants in the endocannabinoid system genes cnr1 and dagla are associated with neurological phenotypes in humans. PLOS ONE, 12(11):e0187926, November 2017. URL: http://dx.doi.org/10.1371/journal.pone.0187926, doi:10.1371/journal.pone.0187926. This article has 50 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0187926)

[12. (Mitjans2013Screening) Marina Mitjans, Alessandro Serretti, Chiara Fabbri, Cristóbal Gastó, Rosa Catalán, Lourdes Fañanás, and Bárbara Arias. Screening genetic variability at the cnr1 gene in both major depression etiology and clinical response to citalopram treatment. Psychopharmacology, 227(3):509–519, February 2013. URL: http://dx.doi.org/10.1007/s00213-013-2995-y, doi:10.1007/s00213-013-2995-y. This article has 47 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00213-013-2995-y)

[13. (Cota2003The) Daniela Cota, Giovanni Marsicano, Matthias Tschöp, Yvonne Grübler, Cornelia Flachskamm, Mirjam Schubert, Dorothee Auer, Alexander Yassouridis, Christa Thöne-Reineke, Sylvia Ortmann, Federica Tomassoni, Cristina Cervino, Enzo Nisoli, Astrid C.E. Linthorst, Renato Pasquali, Beat Lutz, Günter K. Stalla, and Uberto Pagotto. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation, 112(3):423–431, August 2003. URL: http://dx.doi.org/10.1172/jci17725, doi:10.1172/jci17725. This article has 869 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci17725)

[14. (Pagano2007The) Claudio Pagano, Catia Pilon, Alessandra Calcagno, Riccardo Urbanet, Marco Rossato, Gabriella Milan, Katiuscia Bianchi, Rosario Rizzuto, Paolo Bernante, Giovanni Federspil, and Roberto Vettor. The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. The Journal of Clinical Endocrinology &amp; Metabolism, 92(12):4810–4819, December 2007. URL: http://dx.doi.org/10.1210/JC.2007-0768, doi:10.1210/jc.2007-0768. This article has 260 citations.](https://doi.org/10.1210/JC.2007-0768)

[15. (FletcherJones2020Protein) Alexandra Fletcher-Jones, Keri L. Hildick, Ashley J. Evans, Yasuko Nakamura, Jeremy M. Henley, and Kevin A. Wilkinson. Protein interactors and trafficking pathways that regulate the cannabinoid type 1 receptor (cb1r). Frontiers in Molecular Neuroscience, June 2020. URL: http://dx.doi.org/10.3389/fnmol.2020.00108, doi:10.3389/fnmol.2020.00108. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fnmol.2020.00108)

[16. (Blume2016Cannabinoid) Lawrence C. Blume, Theresa Patten, Khalil Eldeeb, Sandra Leone-Kabler, Alexander A. Ilyasov, Bradley M. Keegan, Jeremy E. O’Neal, Caroline E. Bass, Roy R. Hantgan, W. Todd Lowther, Dana E. Selley, and A­llyn C. Howlett. Cannabinoid receptor interacting protein 1a competition with β-arrestin for cb1 receptor binding sites. Molecular Pharmacology, 91(2):75–86, November 2016. URL: http://dx.doi.org/10.1124/mol.116.104638, doi:10.1124/mol.116.104638. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/mol.116.104638)